Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3Muscle Weakness 1Autoimmune Diseases 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × telitacicept × Clear all
NCT06456580 2026-05-07

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Vor Biopharma

Phase 3 Recruiting
180 enrolled

Myasthenia Gravis

NCT07249632 2026-04-09

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

RemeGen Co., Ltd.

Phase 3 Recruiting
120 enrolled

Myasthenia Gravis

NCT05737160 2025-05-23

Study of Telitacicept in Generalized Myasthenia Gravis

RemeGen Co., Ltd.

Phase 3 Completed
114 enrolled

Autoimmune Diseases, Myasthenia Gravis, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡